GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paragon 28 Inc (FRA:7GQ) » Definitions » Debt-to-EBITDA

Paragon 28 (FRA:7GQ) Debt-to-EBITDA : -3.40 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Paragon 28 Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Paragon 28's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.6 Mil. Paragon 28's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €101.1 Mil. Paragon 28's annualized EBITDA for the quarter that ended in Mar. 2024 was €-29.9 Mil. Paragon 28's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -3.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Paragon 28's Debt-to-EBITDA or its related term are showing as below:

FRA:7GQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.1   Med: -0.87   Max: 2.96
Current: -3.65

During the past 5 years, the highest Debt-to-EBITDA Ratio of Paragon 28 was 2.96. The lowest was -4.10. And the median was -0.87.

FRA:7GQ's Debt-to-EBITDA is ranked worse than
100% of 438 companies
in the Medical Devices & Instruments industry
Industry Median: 1.255 vs FRA:7GQ: -3.65

Paragon 28 Debt-to-EBITDA Historical Data

The historical data trend for Paragon 28's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paragon 28 Debt-to-EBITDA Chart

Paragon 28 Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
2.96 0.52 -3.32 -0.87 -4.10

Paragon 28 Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -1.64 -3.43 -2.22 -3.40

Competitive Comparison of Paragon 28's Debt-to-EBITDA

For the Medical Devices subindustry, Paragon 28's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paragon 28's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paragon 28's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Paragon 28's Debt-to-EBITDA falls into.



Paragon 28 Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Paragon 28's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.587 + 100.686) / -24.687
=-4.10

Paragon 28's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.589 + 101.059) / -29.92
=-3.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Paragon 28  (FRA:7GQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Paragon 28 Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Paragon 28's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Paragon 28 (FRA:7GQ) Business Description

Traded in Other Exchanges
Address
14445 Grasslands Drive, Englewood, CO, USA, 80112
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.

Paragon 28 (FRA:7GQ) Headlines

No Headlines